Exploring beyond numeric weight loss: The metabolic effects of semaglutide
<p dir="ltr">The global burden of overweight and obesity has increased by threefold since the 1970s, which led to increased incidences of cardiovascular disease and <u>type 2 diabetes</u>. This review aimed to explore the metabolic impacts of <u>semaglutide</u>...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | |
| منشور في: |
2025
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| الملخص: | <p dir="ltr">The global burden of overweight and obesity has increased by threefold since the 1970s, which led to increased incidences of cardiovascular disease and <u>type 2 diabetes</u>. This review aimed to explore the metabolic impacts of <u>semaglutide</u>, including its effects on hunger and satiety, weight loss maintenance and regain, body composition, lipid profile, and <u>glycemic control</u>. Studies have shown that <u>semaglutide </u>reduced fat mass, particularly <u>visceral fat</u>, while preserving lean muscle mass, as the proportion relative to total body mass decreased by 3.5 % and 2.0 % for total and visceral fat mass, respectively, while it increased by 3.0 % for <u>lean body mass</u>. Also, it enhanced glycemic control, as evidenced by significant reductions in hemoglobin A1C (HbA1c) with the 0.5 mg and 1.0 mg doses. From a baseline range of 8.1–8.7 %, 0.5 mg dose lowered HbA1c by 1.2–1.5 %, while the 1.0 mg dose reduced it by 1.4–1.8 %. Furthermore, semaglutide was the only effective Glucagon Like Peptide-1 Receptor Agonist in reducing Low-Density Lipoprotein and total cholesterol levels, with mean differences of −0.16 mmol/L and −0.48 mmol/L, respectively. Evidence shows that withdrawing semaglutide led to weight regain, while continued treatment resulted in further weight loss. Semaglutide also slowed weight regain and promoted weight loss after failed <u>bariatric surgery.</u> It also significantly reduced ad libitum <u>energy intake</u>, decreased hunger, and increased satiety in multiple trials. Overall, these findings underscore the potential of semaglutide as a comprehensive treatment for obesity and type 2 diabetes.</p><h2>Other Information</h2><p dir="ltr">Published in: Clinical Nutrition ESPEN<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.clnesp.2025.03.010" target="_blank">https://dx.doi.org/10.1016/j.clnesp.2025.03.010</a></p> |
|---|